Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“ESMO26 Dr. Jarushka Naidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations.
And for MOIO in particular – lessons on trial design, non-inferiority, and pragmatism. A must-listen to all involved in trial design.”
You can also read:
